CN104918942A - 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 - Google Patents

嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 Download PDF

Info

Publication number
CN104918942A
CN104918942A CN201480004139.1A CN201480004139A CN104918942A CN 104918942 A CN104918942 A CN 104918942A CN 201480004139 A CN201480004139 A CN 201480004139A CN 104918942 A CN104918942 A CN 104918942A
Authority
CN
China
Prior art keywords
pyrimidine
benzyloxy
hydroxy
isopropyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480004139.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·沃尔克斯托弗
O·索拉尔
N·汉德勒
H·布施曼
S·丘萨克
M·史密斯
S-S·索
R·C·海利
A·希杜里
Z·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Original Assignee
Savira Pharmaceuticals GmbH
F Hoffmann La Roche AG
Europaisches Laboratorium fuer Molekularbiologie EMBL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50070507&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104918942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Savira Pharmaceuticals GmbH, F Hoffmann La Roche AG, Europaisches Laboratorium fuer Molekularbiologie EMBL filed Critical Savira Pharmaceuticals GmbH
Publication of CN104918942A publication Critical patent/CN104918942A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480004139.1A 2013-01-08 2014-01-07 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途 Pending CN104918942A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750017P 2013-01-08 2013-01-08
US61/750,017 2013-01-08
PCT/EP2014/050165 WO2014108406A1 (en) 2013-01-08 2014-01-07 Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease

Publications (1)

Publication Number Publication Date
CN104918942A true CN104918942A (zh) 2015-09-16

Family

ID=50070507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480004139.1A Pending CN104918942A (zh) 2013-01-08 2014-01-07 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途

Country Status (21)

Country Link
US (1) US9045486B2 (https=)
EP (1) EP2943495B1 (https=)
JP (1) JP2016518305A (https=)
KR (1) KR20150103285A (https=)
CN (1) CN104918942A (https=)
AR (1) AR094378A1 (https=)
AU (1) AU2014204889A1 (https=)
BR (1) BR112015012693A2 (https=)
CA (1) CA2894642A1 (https=)
CL (1) CL2015001916A1 (https=)
CR (1) CR20150337A (https=)
EA (1) EA201591291A1 (https=)
HK (1) HK1211286A1 (https=)
IL (1) IL239656A0 (https=)
MA (1) MA38323B1 (https=)
MX (1) MX2015008293A (https=)
PE (1) PE20151722A1 (https=)
PH (1) PH12015501517A1 (https=)
SG (1) SG11201503946UA (https=)
TW (1) TW201443053A (https=)
WO (1) WO2014108406A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
PH12015501492B1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
MX377396B (es) 2013-09-12 2025-03-10 Janssen Biopharma Inc Compuestos de azapiridona y usos de los mismos.
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
SG11201708721XA (en) 2015-04-28 2017-11-29 Shionogi & Co Substituted polycyclic pyridone derivative and prodrug thereof
TW201726678A (zh) 2015-10-30 2017-08-01 赫孚孟拉羅股份公司 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
SG11201804348SA (en) 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2017109088A1 (en) 2015-12-23 2017-06-29 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
ES2881776T3 (es) * 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017158147A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017158151A1 (en) 2016-03-18 2017-09-21 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
JP6961963B2 (ja) * 2016-04-01 2021-11-05 三菱ケミカル株式会社 フルフラールの製造方法
WO2017198744A1 (en) * 2016-05-20 2017-11-23 F. Hoffmann-La Roche Ag Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
DK3464271T3 (da) 2016-05-31 2020-06-15 Kalvista Pharmaceuticals Ltd Pyrazolderivater som plasma-kallikreininhibitorer
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
KR20190018469A (ko) 2016-08-10 2019-02-22 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
PT3716952T (pt) 2017-11-29 2022-04-14 Kalvista Pharmaceuticals Ltd Formas de administração que incluem um inibidor de calicreína plasmática
CN118878544A (zh) 2018-02-28 2024-11-01 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的化合物
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
US20240228495A1 (en) * 2020-03-25 2024-07-11 Sri International Tricyclic Inhibitors of Influenza Virus Endonuclease
EP4074317A1 (en) 2021-04-14 2022-10-19 Bayer AG Phosphorus derivatives as novel sos1 inhibitors
WO2024061300A1 (en) * 2022-09-22 2024-03-28 Insilico Medicine Ip Limited Inhibitors of trex1 and uses thereof
JP2025537492A (ja) 2022-10-19 2025-11-18 アストラゼネカ・アクチエボラーグ ＣＸｓｕｂ３ＣＲ１のモジュレーターとしての２，４，６－三置換１，３，５－トリアジン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US20070161639A1 (en) * 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
EP1906971A2 (en) * 2005-07-27 2008-04-09 Gilead Sciences, Inc. Antiviral compounds
EP2412708A4 (en) 2009-03-26 2014-07-23 Shionogi & Co SUBSTITUTED 3-HYDROXY-4-PYRIDONE DERIVATIVE
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8927710B2 (en) 2009-06-15 2015-01-06 Shionogi & Co., Ltd. Substituted polycyclic carbamoylpyridone derivative
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
尤启东: "《药物化学》", 31 January 2004 *

Also Published As

Publication number Publication date
WO2014108406A1 (en) 2014-07-17
CR20150337A (es) 2015-11-02
US9045486B2 (en) 2015-06-02
PE20151722A1 (es) 2015-11-19
MX2015008293A (es) 2016-06-02
TW201443053A (zh) 2014-11-16
EP2943495B1 (en) 2016-12-28
HK1211286A1 (en) 2016-05-20
JP2016518305A (ja) 2016-06-23
PH12015501517A1 (en) 2015-11-09
HK1212686A1 (en) 2016-06-17
BR112015012693A2 (pt) 2017-07-11
US20140194431A1 (en) 2014-07-10
KR20150103285A (ko) 2015-09-09
MA38323A1 (fr) 2017-02-28
EA201591291A1 (ru) 2015-12-30
AU2014204889A1 (en) 2015-06-11
SG11201503946UA (en) 2015-09-29
AR094378A1 (es) 2015-07-29
CA2894642A1 (en) 2014-07-17
MA38323B1 (fr) 2018-05-31
EP2943495A1 (en) 2015-11-18
IL239656A0 (en) 2015-08-31
CL2015001916A1 (es) 2016-01-22

Similar Documents

Publication Publication Date Title
CN104918942A (zh) 嘧啶酮衍生物和它们用于治疗、改善或预防病毒疾病的用途
TWI542590B (zh) １，２-雙取代雜環化合物
TWI622595B (zh) 充當抗癌劑的經取代核苷衍生物
JP7337502B2 (ja) がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
CN105777756B (zh) 杂芳化合物及其在药物中的应用
CN109952289B (zh) Trpv4拮抗剂
CN115960105A (zh) Kras g12d抑制剂及其在医药上的应用
WO2023109883A1 (zh) 一类芳杂环取代的化合物及其制备方法和用途
CN108218873B (zh) 流感病毒复制抑制剂及其用途
CN114075221B (zh) 取代的杂芳基化合物及其组合物和用途
WO2015127872A1 (zh) 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CN104583211A (zh) 用于抗病毒治疗的化合物和方法
CN105524068A (zh) 氮杂双环衍生物、其制法与医药上的用途
TW202515544A (zh) 作為ｃ－ｋｉｔ激酶抑制劑的醫藥化合物及組合物
CN108191837A (zh) PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用
WO2023020209A1 (zh) 含2-芳杂环取代的脲类化合物、其制备方法和用途
WO2023051495A1 (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
CN117098761A (zh) 咪唑并[4,5-d]哒嗪衍生物、其制备及其治疗性应用
WO2025168124A1 (zh) 喹唑啉类化合物、其药物组合物及其应用
CN104903319A (zh) 萘啶酮衍生物及其在治疗、改善或预防病毒疾病中的用途
CN109705191B (zh) Iap抑制剂及其在药物中的应用
WO2019154053A1 (zh) Iap抑制剂及其在药物中的应用
WO2024061366A1 (zh) 具有磷酰化芳基结构的小分子化合物及其应用
HK40124025A (zh) Ras抑制剂
HK40115101A (zh) 作为kras抑制剂的喹啉化合物

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211286

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150916

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211286

Country of ref document: HK